目的 探討血脂康膠囊與曲克蘆丁聯(lián)合治療動(dòng)脈粥樣硬化血栓性腦梗死的臨床療效。方法 選取2022年9月—2023年9月南陽(yáng)市第二人民醫(yī)院收治的100例動(dòng)脈粥樣硬化血栓性腦梗死患者，按隨機(jī)數(shù)字表法將患者分對(duì)照組（50例）和治療組（50例）。對(duì)照組患者靜脈滴注曲克蘆丁注射液，360 mg加入生理鹽水150 mL，1次/d。在對(duì)照組的基礎(chǔ)上，治療組口服血脂康膠囊，2粒/次，2次/d。兩組治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀改善時(shí)間、日常生活能力量表評(píng)分指數(shù)（Barthel）、腦神經(jīng)功能損傷程度量表（NIHSS）評(píng)分、及血清因子脂蛋白相關(guān)磷脂酶A2（LP-PLA2）、高遷移率族蛋白B1（HMGB1）、氧化低密度脂蛋白（ox-LDL）和血管間黏附分子-1（VCAM-1）水平。結(jié)果 治療后，治療組總有效率為98.00%，明顯高于對(duì)照組總有效率（80.00%，P＜0.05）。治療后，治療組肢體無(wú)力、肢體麻木感、頭痛、眩暈等癥狀改善時(shí)間均明顯短于對(duì)照組（P＜0.05）。治療后，兩組Barthel指數(shù)評(píng)分明顯升高，而NIHSS評(píng)分明顯降低（P＜0.05），且治療組Barthel指數(shù)和NIHSS評(píng)分明顯好于對(duì)照組（P＜0.05）。治療后，兩組血清LP-PLA2、HMGB1、ox-LDL、VCAM-1水平明顯降低（P＜0.05），且治療組明顯低于對(duì)照組（P＜0.05）。結(jié)論 曲克蘆丁與血脂康膠囊協(xié)同治療，可有效改善臨床癥狀，恢復(fù)腦神經(jīng)功能損傷，提高日常生活能力。

Objective To explore the clinical effect of Xuezhikang Capsules combined with troxerutin in treatment of atherosclerotic thrombotic cerebral infarction. Methods Patients (100 cases) with atherosclerotic thrombotic cerebral infarction in Nanyang Second General Hospital from September 2022 to September 2023 were divided into control group (50 cases) and treatment group (50 cases) according to random number table method. Patients in the control group were iv administered with Troxerutin Injection, 360 mg added into normal saline 150 mL, once daily. Patients in the treatment group were po administered with Xuezhikang Capsules on the basis of the control group, 2 grains/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluations were evaluated, the symptom relief time, Barthel and NIHSS scores, and the levels of LP-PLA2, HMGB1, ox-LDL, and VCAM-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.00%, which was significantly higher than that of the control group (80.005%, P < 0.05). After treatment, the improvement time of limb weakness, limb numbness, headache, dizziness and other symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the Barthel index score in two groups was significantly increased, while the NIHSS score was significantly decreased (P < 0.05), and the Barthel index and NIHSS score in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the serum levels of LP-PLA2, HMGB1, ox-LDL, and VCAM-1 in two groups were significantly decreased (P < 0.05), which in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion The synergistic treatment of troxerutin and Xuezhikang Capsules can effectively improve the clinical symptoms, restore the injury of brain nerve function and improve the ability of daily life.

R971

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃聯(lián)合共建項(xiàng)目（LHGJ20191467）；南陽(yáng)市科技計(jì)劃項(xiàng)目（KJGG146）